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Administering Plasmid DNA Encoding Tumor
Vessel–anchored IFN-α for Localizing Gene
Product Within or Into Tumors
Ryan Craig1, Jeffry Cutrera1, Shiguo Zhu1, Xueqing Xia1, Yong-Hwan Lee2 and Shulin Li1
1
Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, Louisiana, USA; 2Department of Biological Sciences,
Louisiana State University, Baton Rouge, Louisiana, USA

Tumor-targeted gene delivery has been intensively
studied in the field of gene therapy, but no attention has
been given to targeting the therapeutic gene products,
which are transcribed and translated from the injected
genes, into tumors. Targeting immune stimulatory gene
products into tumors is the key to triggering tumorspecific CD8+ T-cell responses and reducing systemic
toxicity. To target the gene products generated from the
injected genes into tumors, genes encoding the tumortargeted fusion gene product were generated and
administered locally and systemically via electroporation. As anticipated, administration of a therapeutic gene
encoding IFN-α and the tumor vessel–targeted peptide
CDGRC fusion gene product minimizes the leakage of
immunostimulatory cytokine from tumors into the blood
circulation, increases the infiltration of CD8+ T cells into
tumors, induces a high magnitude of cytotoxic T-cell
lysis (CTL) activity, and reduces tumor vessel density. As
a result, tumor growth was more significantly inhibited
by administering the IFN-α-CDGRC gene than by administering the wild-type IFN-α gene. The same result was
obtained with the systemic administration of the tumortargeted IFN-α gene. This gene product–based tumortargeted gene therapy approach could complement any
other tumor-targeted gene delivery method for improving tumor-targeting efficiency.
Received 16 October 2007; accepted 14 February 2008; published
online 18 March 2008. doi:10.1038/mt.2008.40

INTRODUCTION
One of the most daunting tasks facing the field of cancer therapy
today is finding an effective means of transporting therapeutic
agents to the site of tumors. The most attractive method would
be targeting cell surface proteins that are altered on cancer cells or
in the tumor vasculature. These proteins could be growth factor
receptors,1 cell adhesion molecules,2 integrins,3 or other surface
markers on endothelial cells.
One of the current interests in the field of cancer research lies
in targeting the tumor vasculature, including tumor blood and

lymphatic vessels.4 Endothelial cells line blood vessels and serve as
“gateways” to tumor cells. They contain surface proteins that function as vascular receptors able to transduce growth or angiogenic
signals.2 The main advantage of targeting endothelial cells is that
they are highly accessible from the blood stream, thus simplifying
the experimental design.
Several peptides express high affinity for endothelial markers,
such as RGD-4C (ACDCRGDCFCG) for integrins5 or CNGRC
for aminopeptidase N/CD13.2 Of the 25 known integrins, eight
bind to peptides containing the sequence RGD, which serves as
the main integrin recognition site in extracellular matrix proteins.6
The RGD-4C peptide shows high affinity for αvβ5 and αvβ3 integrins.7 Integrin αvβ3 is highly expressed in endothelial cells of
angiogenic vessels and exhibits high affinity for matrix metalloproteinase-2.8 The αvβ3 receptor binds to a wide range of ligands
including, but not limited to, fibronectin, vitronectin, osteopontin,
and fibrinogen.9
The specificity of the sequence RGD-4C for αvβ5 and αvβ3 integrins makes this peptide a competitive candidate for targeting
DNA vectors to the tumor vasculature. In fact, this peptide has
been integrated as part of adenovirus surface proteins and has
been heavily explored for targeting the virus into αvβ3 expressing endothelial and tumor cells via the RGD-4C–αvβ3 interaction, instead of using the natural coxsackievirus and adenovirus
receptors that are often lost in highly malignant tumor cells.10
Curnis et al. showed that coupling tumor necrosis factor-α with
αvβ3 ligands improves its antiangiogenic activity.11 They reported
that subnanogram doses are enough to induce antitumor effects
when tumor necrosis  factor is fused with ACDCRGDCFCG
(RGD-4C) and coadministered with chemotherapeutic drugs
like melphalan. de Groot et al. developed a doxorubicin prodrug conjugated to RGD-4C for reducing the systemic toxicity
of doxorubicin.12
Interferon (IFN)-α has been shown to inhibit tumor growth
by enhancing the antitumor immune response,13 preventing
angiogenesis in the tumor vasculature,14 and inducing apoptosis
of tumor cells.15 It is effective in treating several cancers including renal cell carcinoma,16 hairy cell leukemia,17 malignant
melanoma,18 basal cell carcinoma,19 squamous cell carcinoma
of the head and neck,20 and multiple myelomas.21 However,
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IFN-α protein therapy is toxic and expensive.22,23 A high level
of IFN-α protein in the tumor is required for maximizing the
therapeutic efficacy.24
To reduce the cost and increase the accumulation of IFN-α
in tumors, we have generated a fusion gene encoding IFN-α and
CDGRC peptide (IFNα-CDGRC). Administration of this fusion
gene via intratumoral electroporation enhances anchorage of the
fusion gene product into tumors and significantly improves the
therapeutic efficacy. As far as we know, this is the first report of
using a gene therapy approach to simultaneously express and
target the gene product into tumors for increasing the accumulation of the gene product in the tumors and enhancing antitumor
efficacy via either local or distant tumor delivery.

RESULTS
CDGRC, CNGRC, and RGD-4C containing reporter
gene products illustrate similar tumor
anchorage activity
Most tumor-targeted strategies have been used for systemic gene
or vector delivery, but the study described here aims to anchor
the tumor vessel–targeted gene product from the intratumoral
injected IFNα-CDGRC gene at the tumor sites. The purpose of this
strategy is to prevent the leakage of the therapeutic gene product
from the injected tumor sites into blood circulation, thus increasing the accumulation of IFN-α in local tumors. An increased level
of IFN-α and interleukin-12 in the tumor is required for maximizing the therapeutic efficacy.25,26
To yield a tumor vessel–anchored gene product, three rep
orter fusion genes encoding secreted alkaline phosphatase
(SEAP) and tumor vessel–anchored peptides, CDGRC, CNGRC,
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Figure 1 Tumor vessel–anchored binding activity from fusion gene
products and targeted peptides. (a) Structures of wild-type and tumor
vessel–anchored secreted alkaline phosphatase (SEAP) reporter genes
encoding SEAP and CDGRC, CNGRC, or RGD-4C. (b) The ratio of SEAP
expression between tumors and a combination of livers, spleens, and
hearts. (c) The ratio of SEAP expression between tumors and livers.
(d) Inhibition of anti-CD13 antibody binding to endothelial cells (EC40)
with tumor vessel-anchored gene product. (e) Structural analysis of DGR
peptide–binding activity using the known crystal structure of the integrin
αvβ3. The ligand peptide and Mn++ ion are shown as a stick model and a
ball, respectively, with color-coded atoms: red, oxygen; blue, nitrogen;
yellow, carbon; and cyan, Mn++. The ligand binding site in the integrin
complex is represented as a surface diagram with color-coded surface
electropotentials: red, negative; blue, positive; and white, neutral. CMV,
cytomegalovirus.
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and CDCRGDCFC (RGD-4C), were generated (Figure 1a).
The  selection of mini peptides, instead of a large antibody,
for anchoring the therapeutic gene product may reduce the
concern about  immunogenicity. Also, the selected CDGRC
shares its  homology with both the core tumor vessel–targeted
peptide, RGD-4C, and the other well-characterized tumortargeted peptide, CNGRC.27–29 To test whether the tumoranchorage activity levels of SEAP gene products using RGD-4C,
CDGRC, and CNGRC peptides were comparable, the expression of SEAP was  determined in the liver, spleen, lung, heart,
and tumors, and the expression indexes between tumors and
livers and between tumors and overall tissues were determined.
As expected, the SEAP activities were primarily detected in
tumors as illustrated by the large ratios between tumors and
tissues with no  significant difference among the three tested
peptides (Figure 1b and c).
It is known that DGR-containing peptides bind to the tumor
vessel integrin αvβ3 (ref. 30). This binding is made by a strong salt
bridge formed between Arg (R) of the peptide and the negatively
charged residues in the integrin. Although the continued high
negative potential in the ligand Asp (D) binding site may cause
a negative effect on this peptide binding, this pocket is occupied by Mn++. As a result, the ligand Asp is in direct contact
with this metal ion, providing an additional salt bridge and, ultimately, enhancing binding of the peptide (Figure 1e). If Asn (N)
is in the ligand, as in NGR, instead of Asp (D), the salt bridge
between Asn and Mn++ may not be formed, resulting in a significant loss in binding force. Thus, NGR cannot effectively bind to
the integrin due to the missing interaction between Mn++ and
the Asp in the peptide ligand.
Next, we examined whether CDGRC binds to CD13, the
receptor for CNGRC.28 To determine the binding activity of
CDGRC to CD13, a cell-binding competition assay was performed between reporter gene products (SEAP-CDGRC, SEAPCNGRC, and SEAP) and the anti-CD13 antibody in a murine
endothelial cell line (EC40). This strategy was chosen because
antibodies in general have a very high–binding affinity compared to other competitor molecules, and illustration of any
competition from the high-affinity antibody binding by these
mini peptide–containing SEAP gene products would be a strong
indicator that this peptide binds to the target CD13 receptor.
Indeed, SEAP-CDGRC illustrates a similar level of inhibition
on the anti-CD13 antibody-mediated binding to the endothelial cells as CNGRC-SEAP (Figure 1d). This result is a clear
indication that the CDGRC not only binds αvβ3 as found by
the other group30 but also binds as effectively as CNGRC to the
CD13 (Figure 1d).
The dual binding activity by the CDGRC illustrated above
provided the basis for selecting this peptide encoding sequence to
generate a CDGRC and IFN-α-encoding fusion gene (Figure 2a).
To determine whether the fusion therapeutic gene product is able
to anchor to tumors, the expression levels of IFN-α and tumoranchored IFNα-CDGRC in tumors and blood were determined
after intratumoral administration of the genes via electroporation. The expression index between tumors and blood illustrates
a fourfold higher level of accumulation of IFNα-CDGRC than
IFN-α (Figure 2b).
www.moleculartherapy.org vol. 16 no. 5 may 2008
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Figure 2 Expression of tumor-anchored IFNα-CDGRC via administration of plasmid DNA encoding IFN-α and the tumor vessel–anchored
mini peptide, CDGRC. (a) Structure of wild-type IFN-α gene (pIFNα)
and the tumor vessel–anchored IFN-α gene (pIFNα-CDGRC). (b) The
expression ratio of IFN-α and tumor vessel–anchored IFN-α between
tumors and blood. Plasmid DNA encoding IFN-α, IFN-α-CDGRC, or
no transgene was administered into SCCVII tumors via electroporation
(20 µg/tumor, n = 4) at the indicated electroporation parameters
(see Materials and Methods). Tumors and blood were collected for
determining the level of IFN-α 24 hours after the administration. CMV,
cytomegalovirus; IFN-α, interferon-α.

IFNα-CDGRC is more effective than wild-type IFN-α
in reducing tumor vessel density and inducing CD8+
T–cell immune response
IFN-α plays multiple roles in the inhibition of tumor growth,
including the induction of antitumor immune response,13 inhibition of angiogenesis in the tumor vasculature,14 and enhancement
of tumor-cell apoptosis.15 These effects by tumor vessel–anchored
IFNα-CDGRC gene therapy and wild-type IFN-α gene therapy
were compared in SCCVII tumors.
Intratumoral administration of plasmid DNA encoding tumor
vessel–anchored IFNα-CDGRC reduces vessel density by 40%,
and administration of the wild-type IFN-α gene reduces the vessel
density by 13% (Figure 3a), which shows threefold more inhibition achieved by the tumor vessel–anchored IFNα-CDGRC gene
therapy than wild-type IFN-α gene therapy (P = 0.00017). In fact,
large necrosis areas were found in all tumors receiving tumor
vessel–anchored IFNα-CDGRC gene therapy, but were found only
in ~25% of tumors receiving wild-type IFN-α gene therapy. This
necrosis by tumor vessel–anchored IFNα-CDGRC gene therapy
may be partially caused by inhibition of tumor vessel development
and partially caused by an enhanced cell death because the terminal
uridine deoxynucleotidyl transferase dUTP nick end labeling assay
results illustrated a larger area of apoptosis by IFNα-CDGRC than
wild-type IFN-α gene therapy (data not shown).
To illustrate the antitumor immune response, the infiltration of
both CD4+ and CD8+ T cells into tumors was compared between
tumor vessel–anchored IFNα-CDGRC and wild-type IFN-α gene
therapy. Tumor vessel–anchored IFN-α gene therapy was found to
be three times more effective than wild-type IFN-α gene therapy
in inducing infiltration of CD8+ T cells (P = 0.042), but no difference was detected in the infiltration of CD4+ T cells between these
treatment groups (Figure 3c).
Molecular Therapy vol. 16 no. 5 may 2008
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Figure 3 Inhibition of tumor vessel density and enhancement of
CD8+ T-cell infiltration by administering IFNα-CDGRC over wild-type
IFN-α. Plasmid DNA encoding wild-type IFN-α (pIFNα), tumor  vessel–
anchored IFNα-CDGRC (pIFNα-CDGRC), and no transgene (pCtrl),
respectively, was administered into SCCVII tumors (20 µg/mouse) via
electroporation. Ten days after one treatment, tumors were collected,
sectioned, and immunostained with anti-CD31, -CD8, and -CD4
antibodies (n = 9). Five days after the second treatment (n = 5), spleens
were collected for determining the cytotoxic T-cell lysis (CTL) activity
against tumor cells in the presence of anti-NK antibody for avoiding
detection of any NK cell–mediated tumor-cell death. (a) Tumor vessel
density from different treatment groups (P = 0.00017 for pIFNα versus
pIFNα-CDGRC). (b) Infiltration of CD8+ T cells from different treatment
groups (P = 0.042 for pIFNα versus pIFNα-CDGRC). (c) Infiltration of
CD4+ T cells from two treatment groups. (d) CTL activity in the two treat
ment groups (P = 0.0057). CMV, cytomegalovirus; IFN-α, interferon-α;
NK cell, natural killer cell.

To determine whether tumor vessel–anchored IFNα-CDGRC
gene therapy induces a higher level of cytotoxic T-cell lysis (CTL)
activity than wild-type IFN-α gene therapy, CTL activity was
compared in mice that received two types of therapeutic genes.
As expected, tumor vessel–anchored IFNα-CDGRC gene therapy
induces ~20–30% higher levels of CTL activity than wild-type
IFN-α gene therapy (Figure 3d).

Tumor vessel–anchored IFN-α gene therapy is more
effective in inhibition of tumor growth than
wild-type IFN-α gene therapy
To examine the therapeutic efficacy, tumor volumes were measured following the administration of tumor vessel–anchored
IFNα-CDGRC and wild-type IFN-α encoding genes. CDGRC
alone was omitted in the treatment groups because the maximum
level of IFNα-CDGRC protein was between 6 and 8 ng/mg protein
in tumor tissues and this level of CDGRC was found to have no
effect on tumor growth inhibition in our preliminary study (as
determined by administering the reporter fusion gene encoding
SEAP and SEAP-CDGRC) (data not shown).
An increased inhibition of tumor growth was detected by
administration of the tumor vessel–anchored gene in two independent studies (Figure 4a and b; P < 0.05). The true tumor volume
reduction by tumor vessel–anchored gene therapy may actually
be more significant than the tumor volume shown in Figure 4
because all tumors using this tumor-anchored gene therapy contain necrotic areas, but the tumor volume measurement is based on
the diameters from the edges for easy measurement.
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Tumor vessel–targeted IFN-α gene therapy is also
effective when delivered systemically
To determine whether the IFNα-CDGRC gene therapy demonstrates a stronger antitumor efficacy when it is administered
systemically, both wild-type IFN-α and IFNα-CDGRC were
administered into hindlimb muscles or skin via electroporation
in a colon tumor–bearing model. Administration to muscles
or skin was counted as systemic delivery because the injected
tissues are distal from tumors and the gene products made from
the injected tissues were secreted into blood circulation. After
administration, inhibition levels of tumor growth and antitumor
CTL activity were compared. Increased inhibition of tumor
growth and increased CTL activity are the ultimate surrogate
end points for the enhanced IFN-α accumulation because tumorspecific accumulation of immune stimulatory cytokines is the key
to inducing effective antitumor response and CTL activity.24–26 As
is also found from intratumoral administration, IFNα-CDGRC
yields a much better tumor growth inhibition from systemic
delivery than the wild-type IFN-α (Figure 5a). Likewise, IFNαCDGRC induces much stronger CTL activity than wild-type IFN-α
with this systemic delivery (Figure 5b). These results illustrate
that tumor-targeted IFNα-CDGRC gene therapy is beneficial for
treating tumors with both systemic and local administrations.

DISCUSSION
The major goal of this study was to determine whether administering IFN-α gene encoding the tumor-targeted IFN-α gene
product (IFNα-CDGRC) into tumors via intratumoral electroporation would increase the therapeutic efficacy and improve
the antitumor immune response. Our results support the tumoranchoring assumption because a fourfold higher level of IFNαCDGRC was accumulated in tumors compared to wild-type
IFN-α, in two independent experiments (Figure 1). Because this
tumor-anchoring approach occurs after protein translation and
protein secretion outside of cells, it can complement other tumortargeted gene delivery approaches occurring at the delivery and
transcriptional levels to achieve double or triple tumor-targeting
effects. For example, this anchoring strategy complements the
tumor-targeted electroporation injection for accumulating the
therapeutic cytokine product IFNα-CDGRC at the injected tumors
(Figure 1). Associated with this accumulation, a significant infiltration of CD8+ T cells and inhibition of tumor angiogenesis were
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Figure 4 Comparison of tumor growth inhibition between pIFNαCDGRC versus pIFNα gene therapy via local tumor administration.
SCCVII tumor-bearing mice (n = 4) were treated with 20 µg of pCtrl
(control), pIFNα, and pIFNα-CDGRC plasmid DNA in a volume of 30 µl
saline via intratumoral administration and electroporation. (a,b) Two
administrations were performed at 10 days apart. Two independent
experiments were performed. IFN-α, interferon-α.
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Figure 5 Comparison of tumor growth inhibition and tumor-specific
CTL activity between systemic expression of tumor-anchored IFNαCDGRC and wild-type IFN-α. DNA was injected into skins (the first
administration) and muscles (the second administration) located distant
from tumors (n = 6). Two administrations were performed at 10 days
apart at a dose of 10 µg/mouse in a volume of 30 µl saline. (a) Inhibition
of tumor growth after systemic expression of IFN-α and tumor-anchored
IFNα-CDGRC. (b) Tumor-specific CTL activities following expression of
two types of IFN-α. Spleen cells were isolated for CTL activity assay 7
days after the second administration. CTL, cytotoxic T-cell lysis; IFN-α,
interferon-α.

achieved by administering this IFNα-CDGRC gene, compared to
administering the wild-type IFN-α gene (Figure 3).
As was found from local tumor delivery, systemic adminis
tration of tumor-targeted IFNα-CDGRC also enhances tumor
growth inhibition and tumor-specific CTL activity (Figure 5).
These results suggest that this tumor-targeted gene therapy not
only can complement other tumor targeted delivery approaches
for enhancing antitumor efficacy but also works independently
for enhancing antitumor efficacy. In summary, the local tumor
and distal administration results support the assumption that
accumulation of immune stimulatory cytokines into tumor is the
key to triggering a significant antitumor response. This notion
was also found to be true for interleukin-12-mediated antitumor
efficacy.25,26 The results from this study and the interleukin-12
administration route study conducted previously suggest that
different immune stimulatory cytokines may share the same
principal,25,26 which is that tumor-specific accumulation of these
cytokines boost tumor-specific antitumor immune response.
Unlike antibody- or peptide-mediated recombinant cytokine
protein tumor targeting,31,32 this study uses a gene therapy
approach to express the tumor-anchored gene product containing
a mini-CDGRC peptide and IFN-α. This peptide shares the identical RGD-4C core sequence (Figure 1) and also has a high homology with the mini-tumor vessel–targeted peptide CNGRC that
binds aminopeptidase N.2 The structure of amino acids “D” and
“N” that appear in CDGRC and CNGRC, respectively, is almost
identical, which suggests that the CDGRC peptide not only binds
the integrin αvβ3 (ref. 30) but also aminopeptidase N.28 Indeed, the
competition study demonstrates that CDGRC-SEAP is as effective
as CNGRC-SEAP in inhibiting the binding of the high-affinity
anti-CD13 antibody (5 µg total antibody) (Figure 1d). However,
CNGRC does not bind αvβ3 favorably despite its similarity to
CDGRC, according to the structural analysis (Figure 1e).
A cyclic peptide, CDGRC, was used because a cyclic structure is
more effective than linear NGR motifs in receptor:ligand binding.33
This short peptide, containing only five amino acids, has much less
chance to induce immunogenicity than a large polypeptide as determined from the CNGRC study.34 Therefore, this strategy has great
potential for anchoring the gene product in tumors without triggering immunogenicity against the therapeutic gene product itself.
www.moleculartherapy.org vol. 16 no. 5 may 2008
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Others have demonstrated that the CNGRC-TNFα conjugated protein is more effective in treating tumors than the wildtype tumor necrosis factor-α at a low dose.35 This observation may
apply to gene therapy as illustrated in this study, in which tumoranchored IFNα-CDGRC gene therapy is more effective than wildtype IFN-α gene therapy for treating tumors. The advantage of the
electroporation gene therapy approach is that it is easier and less
expensive than recombinant protein therapy. From an economic
point of view, this gene therapy strategy has great potential.

MATERIALS AND METHODS
Gene constructs encoding tumor vessel–anchored reporter gene products
and therapeutic gene product. SEAP gene constructs encoding fusion

protein SEAP and tumor vessel–targeted peptides CDGRC, CNGRC,
or RGD-4C were generated via direct PCR. The same forward primer
5ʹ-GCATCATCCCAGTTGAGGAG-ʹ was used for generating fusion genes
SEAP-CDGRC, SEAP-CNGRC, and SEAP-RGD-4C. The reverse primers were 5ʹ-GTAGGATCCTTATCAGCATCTTCCATCGCATGTCTGC
TCGAAGCGGCCGGC-3ʹ for generating SEAP-CDGRC fusion gene, 5ʹTTATCAACAACGACCGTTACATGTCTGCTCGAAGCGGCCGG-3ʹ
for generating SEAP-CNGRC fusion gene, and 5ʹ-TTATCAGCAGAA
ACAATCACCGCGGCAATCACA-3ʹ for generating SEAP-RGD-4C
fusion gene. The PCR product was cloned into pCR2.1 TA cloning vector
(Invitrogen, Carlsbad, CA), and then subcloned into a vector containing
a cytomegalovirus promoter, a mini-intron, wild-type SEAP gene, and a
human growth hormone polyadenylation signal using restriction enzymes
BamH1 and SpeI (Figure 1). The sequence was confirmed by sequence
analysis and reporter gene activity assay.
Using the same strategy, IFNα-CDGRC encoding gene construct was
generated (Figure 2). In brief, the forward and reverse primers used for
generating DNA fragment encoding IFNα-CDGRC were 5ʹ-GTAAGC
TTATGGCTAGGCTCTGTGCTTTCC-3ʹ and 5ʹ-TCAGCATCTTCCAT
CGCACTCCTTCTCCTCACTCAGTCT-3ʹ. The PCR product containing
IFNα-CDGRC encoding sequence was cloned into pCR2.1 TA cloning
vector. The IFNα-CNGRC fusion gene was released from this vector with
HindIII and SpeI restriction digestion enzymes and subcloned into an
expression vector cut with HindIII and SpeI. The expression vector for this
fusion gene is the same as the one expressing the wild-type IFN-α (Figure 2).
The fusion gene sequence was confirmed by sequence analysis.

Gene Product Tumor Auto-targeted Gene Therapy

syringe followed by electroporation. After 1 day, the tumors and organs
were harvested, sectioned at 10 µm, and the expression of reporter genes
was measured using a SEAP activity assay kit (Tropix, Bedford, MA).
Using the same administration approach, plasmid DNA encoding IFN-α
and IFNα-CDGRC was administered and the level of IFN-α was detected
using a kit from PBL Biomedical Laboratories (Piscataway, NJ).
Fluorescent microscope-based CTL assay. Cytotoxic T-lymphocyte (CTL)

activity was evaluated using a CyToxiLux kit (OncoImmunin, Gaithersburg,
MD), a single–cell–based fluorogenic cytotoxicity assay.40 Splenocytes were
obtained from SCCVII tumor-bearing C3H mice 2 weeks after treatment.
These splenocytes are referred to as effector cells. The effector cells were
primed by coculture with mitomycin C–treated SCCVII tumor cells in a
ratio of 25:1 for 5 days in Rosewell Park Memorial Institute-1640 medium
with 20% fetal calf serum. Effector cells were incubated with red fluorescence–labeled target SCCVII cells in the indicated ratios in a volume of
200 µl for 16 hours. The apoptotic target cells (red/yellow colored cells)
were examined using an Olympus BX41 fluorescence microscope. CTL
activity was calculated using the equation: percentage specific killing =
100 × (apoptotic target cells − spontaneous apoptotic target cells)/(total
target cells).
Immunostaining of T-cell infiltration. The procedures for frozen-block
preparation, tissue sectioning, and immunostaining were the same as
described previously.37–39,41 The primary antibody applied to the sections
was anti-CD8 (1:400; Santa Cruz Biotechnology, Santa Cruz, CA).
Flow cytometric analysis of CD13 expression. EC40 (American Type

Culture collection, Manassas, VA) cells were stained with phycoerythrinlabeled anti-CD13 receptor antibody (BD Biosciences, San Jose, CA) in the
presence of tumor lysates containing 50 ng protein of SEAP, SEAP-CDGRC,
or SEAP-CNGRC. The stained cells were analyzed using FACscan cytometer (BD Biosciences, San Jose, CA). A total of 10,000 cells/sample were
acquired and data samples were analyzed using Cellquest software.
Structural binding analysis. The binding activity of DGR and NGR to

the known RGD-binding integrin αvβ3 was analyzed. The coordinates for
the RGD peptide and αvβ3 integrin were obtained from the pdb “1L5G”.42
Protein surface electropotential was calculated using apbs-0.5.1 (ref. 43) and
the protein surface diagram and the ligand stick model were drawn using
PyMol Molecular Graphics System (DeLano Scientific, San Carlos, CA).

Tumor models and DNA delivery via electroporation. Six- to eight-weekold female C3H/HeN or Balb/c mice, weighing 18–20 g, from the in-house
animal breeding facility were used for this study and were maintained under
National Institutes of Health guidelines, approved by the Institutional
Animal Care and Use Committee of Louisiana State University.
SCCVII and CT26 cell lines were maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum (Life Technologies,
Rockville, MD). SCCVII and CT26 tumors were generated by sub
cutaneously inoculating the mice with 2 × 105 tumor cells in a 30-µl
volume into C3H and Balb/c mice, respectively. Tumor dimensions were
measured with calipers, and volumes were calculated from the formula:
V = (π/8)(a × b2), where V = tumor volume, a = maximum tumor diameter,
and b = diameter at 90° to “a”.36 Using the protocols described previously,
plasmid DNA was injected into tumors, skins and muscles. Each injection
was followed by immediate electroporation.37,38 The parameters for
intratumoral electroporation were previously set at 450 V/cm and 20 ms
pulse duration for 2 pulses.37 The parameters for intramuscular and
intradermal electroporation were 350 V/cm, 20 ms pulse duration for 2
pulses.39 The endotoxic free plasmid DNA was prepared using Qiagen
Endotoxic free plasmid DNA preparation kit (Germantown, MD).

Statistical analysis. Tumor volume, CD8+ T-cell infiltration, and vessel

Gene expression analysis. In brief, tumors were injected with plasmids

7.

that expressed SEAP-CDGRC, SEAP-CNGRC, or SEAP-RGD-4C with a

Molecular Therapy vol. 16 no. 5 may 2008

density were the primary outcomes measured. We used the two-sided
Student’s t-test to compare individual treatments. P values <0.05 were considered statistically significant.
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